impower110: atezolizumab vs chemo in pd-l1–selected nsclc
Published 4 years ago • 1.1K plays • Length 4:18Download video MP4
Download video MP3
Similar videos
-
1:12
cityscape: 1l tiragolumab atezolizumab vs placebo atezolizumab in pd-l1-selected nsclc
-
1:49
phase 3 trials of atezolizumab versus standard chemotherapy in pd-l1-selected nsclc
-
3:17
impower010: os results of atezolizumab vs best supportive care in resected nsclc
-
1:41
adjuvant atezolizumab in nsclc
-
3:19
frontline pd-l1 monotherapy: keynote-042 and impower110
-
2:44
disease-free survival in impower010 trial: adjuvant atezolizumab in nsclc
-
2:52
pd-l1 and tmb as biomarkers in the imvigor211 trial of atezolizumab vs. chemo for bladder cancer
-
6:20
atezolizumab for locally advanced or metastatic pd-l1-selected nsclc
-
8:20
impower010: atezolizumab versus best supportive care after adjuvant chemotherapy in resected nsclc
-
4:48
keynote-091 and impower010: adjuvant chemotherapy for nsclc
-
1:06
fort 05-beat: comparing 1l atezolizumab vs atezolizumab bevacizumab in pd-l1 high nsclc
-
4:50
impower010: adjuvant atezolizumab improves dfs in resected stage ii-iiia nsclc
-
1:21
assessing the impact of atezolizumab in nsclc
-
1:50
pd-l1 agents in the treatment of nsclc
-
3:27
#esmo21 highlights on patterns of relapse in nsclc to atezolizumab vs bsc after adj ct: impower010
-
5:05
anti–pd-l1 atezolizumab or chemotherapy as second-line therapy in patients with sclc
-
2:18
final os results of imvigor130: 1l atezolizumab /- chemotherapy in metastatic urothelial carcinoma
-
5:36
ipsos: 1l atezolizumab vs single-agent chemotherapy in patients with platinum-ineligible nsclc
-
5:06
subgroup analysis of oak trial data supports use of atezolizumab in patients with nsclc